Second Clinical Batch Released for Immediate Patient Use

Summary by 6ix AI

The supply from this batch is sufficient to complete dose escalation and begin patient dose expansion in blood cancers. A third batch is expected to be available soon, which will help complete the phase one trial. The company is also activating new clinical sites to facilitate patient recruitment and treatment.

Written by 6ix AI from the company’s filing. How 6ix writes summaries